Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Algazi AP, Othus M, Daud AI, Lo RS, et al. Nat Med 2020;26:1564-1568.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Algazi AP, Othus M, Daud AI, Lo RS, et al. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med 2020;26:1564-1568.
PMID: 33020646